{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:37:58Z","timestamp":1793968678253,"version":"4.8.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Relmada Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This review article presents select recent studies that form the basis for the development of esmethadone into a potential new drug. Esmethadone is a promising member of the pharmacological class of uncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonists that have shown efficacy for major depressive disorder (MDD) and other diseases and disorders, such as Alzheimer\u2019s dementia and pseudobulbar affect. The other drugs in the novel class of NMDAR antagonists with therapeutic uses that are discussed for comparative purposes in this review are esketamine, ketamine, dextromethorphan, and memantine. We present in silico, in vitro, in vivo, and clinical data for esmethadone and other uncompetitive NMDAR antagonists that may advance our understanding of the role of these receptors in neural plasticity in health and disease. The efficacy of NMDAR antagonists as rapid antidepressants may advance our understanding of the neurobiology of MDD and other neuropsychiatric diseases and disorders.\n<\/jats:p>","DOI":"10.1007\/s00406-023-01571-4","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T20:02:30Z","timestamp":1678305750000},"page":"1463-1476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Esmethadone-HCl (REL-1017): a promising rapid antidepressant"],"prefix":"10.1007","volume":"273","author":[{"given":"Maurizio","family":"Fava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"De Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mattarei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezio","family":"Bettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Comai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Alimonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bifari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Folli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Guidetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Sgrignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"O\u2019Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Traversa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Inturrisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pappagallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo L.","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"1571_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-022-01661-0","author":"J Moncrieff","year":"2022","unstructured":"Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA (2022) The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry\u00a0https:\/\/doi.org\/10.1038\/s41380-022-01661-0","journal-title":"Mol Psychiatry"},{"key":"1571_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/bmjebm-2019-111238","volume":"25","author":"JC Jakobsen","year":"2020","unstructured":"Jakobsen JC, Gluud C, Kirsch I (2020) Should antidepressants be used for major depressive disorder? BMJ Evid Based Med 25:130\u2013130. https:\/\/doi.org\/10.1136\/bmjebm-2019-111238","journal-title":"BMJ Evid Based Med"},{"key":"1571_CR3","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2165\/11633130-000000000-00000","volume":"72","author":"DC Mathews","year":"2012","unstructured":"Mathews DC, Henter ID, Zarate CA (2012) Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs 72:1313\u20131333. https:\/\/doi.org\/10.2165\/11633130-000000000-00000","journal-title":"Drugs"},{"key":"1571_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/pcn.12604","volume":"72","author":"S Boku","year":"2018","unstructured":"Boku S, Nakagawa S, Toda H, Hishimoto A (2018) Neural basis of major depressive disorder: beyond monoamine hypothesis. Psychiatry Clin Neurosci 72:3\u201312. https:\/\/doi.org\/10.1111\/pcn.12604","journal-title":"Psychiatry Clin Neurosci"},{"key":"1571_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/HRP.0000000000000183","volume":"26","author":"ID Henter","year":"2018","unstructured":"Henter ID, de Sousa RT, Zarate CA Jr (2018) Glutamatergic modulators in depression. Harv Rev Psychiatry 26:307\u2013319. https:\/\/doi.org\/10.1097\/HRP.0000000000000183","journal-title":"Harv Rev Psychiatry"},{"key":"1571_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.neuron.2016.12.015","volume":"93","author":"RA Nicoll","year":"2017","unstructured":"Nicoll RA (2017) A brief history of long-term potentiation. Neuron 93:281\u2013290. https:\/\/doi.org\/10.1016\/j.neuron.2016.12.015","journal-title":"Neuron"},{"key":"1571_CR7","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1085\/jgp.201812032","volume":"150","author":"KB Hansen","year":"2018","unstructured":"Hansen KB, Yi F, Perszyk RE, Furukawa H, Wollmuth LP, Gibb AJ, Traynelis SF (2018) Structure, function, and allosteric modulation of NMDA receptors. J Gen Physiol 150:1081\u20131105. https:\/\/doi.org\/10.1085\/jgp.201812032","journal-title":"J Gen Physiol"},{"key":"1571_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.nlm.2016.08.017","volume":"134","author":"K Mahati","year":"2016","unstructured":"Mahati K, Bhagya V, Christofer T, Sneha A, Shankaranarayana Rao BS (2016) Enriched environment ameliorates depression-induced cognitive deficits and restores abnormal hippocampal synaptic plasticity. Neurobiol Learn Mem 134:379\u2013391. https:\/\/doi.org\/10.1016\/j.nlm.2016.08.017","journal-title":"Neurobiol Learn Mem"},{"key":"1571_CR9","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1017\/S0033291712002085","volume":"43","author":"E Bora","year":"2013","unstructured":"Bora E, Harrison BJ, Y\u00fccel M, Pantelis C (2013) Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol Med 43:2017\u20132026. https:\/\/doi.org\/10.1017\/S0033291712002085","journal-title":"Psychol Med"},{"key":"1571_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrn849","volume":"3","author":"JJ Kim","year":"2002","unstructured":"Kim JJ, Diamond DM (2002) The stressed hippocampus, synaptic plasticity and lost memories. Nat Rev Neurosci 3:453\u2013462. https:\/\/doi.org\/10.1038\/nrn849","journal-title":"Nat Rev Neurosci"},{"key":"1571_CR11","doi-asserted-by":"publisher","first-page":"eaat8078","DOI":"10.1126\/science.aat8078","volume":"364","author":"RN Moda-Sava","year":"2019","unstructured":"Moda-Sava RN, Murdock MH, Parekh PK, Fetcho RN, Huang BS, Huynh TN, Witztum J, Shaver DC, Rosenthal DL, Alway EJ, Lopez K, Meng Y, Nellissen L, Grosenick L, Milner TA, Deisseroth K, Bito H, Kasai H, Liston C (2019) Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science 364:eaat8078. https:\/\/doi.org\/10.1126\/science.aat8078","journal-title":"Science"},{"key":"1571_CR12","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1176\/appi.ajp.161.11.1957","volume":"161","author":"P Videbech","year":"2004","unstructured":"Videbech P, Ravnkilde B (2004) Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 161:1957\u20131966. https:\/\/doi.org\/10.1176\/appi.ajp.161.11.1957","journal-title":"Am J Psychiatry"},{"key":"1571_CR13","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.biopsych.2005.01.016","volume":"57","author":"A Neumeister","year":"2005","unstructured":"Neumeister A, Wood S, Bonne O, Nugent AC, Luckenbaugh DA, Young T, Bain EE, Charney DS, Drevets WC (2005) Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol Psychiatry 57:935\u2013937. https:\/\/doi.org\/10.1016\/j.biopsych.2005.01.016","journal-title":"Biol Psychiatry"},{"key":"1571_CR14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1190287","volume":"329","author":"N Li","year":"2010","unstructured":"Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959\u2013964. https:\/\/doi.org\/10.1126\/science.1190287","journal-title":"Science"},{"key":"1571_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature10130","volume":"475","author":"AE Autry","year":"2011","unstructured":"Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng P-f, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91\u201395. https:\/\/doi.org\/10.1038\/nature10130","journal-title":"Nature"},{"key":"1571_CR16","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1038\/s41386-019-0501-x","volume":"44","author":"MV Foga\u00e7a","year":"2019","unstructured":"Foga\u00e7a MV, Fukumoto K, Franklin T, Liu R-J, Duman CH, Vitolo OV, Duman RS (2019) N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects. Neuropsychopharmacology 44:2230\u20132238. https:\/\/doi.org\/10.1038\/s41386-019-0501-x","journal-title":"Neuropsychopharmacology"},{"key":"1571_CR17","doi-asserted-by":"publisher","first-page":"12196","DOI":"10.3390\/ijms232012196","volume":"23","author":"SM Stahl","year":"2022","unstructured":"Stahl SM, De Martin S, Mattarei A, Bettini E, Pani L, Guidetti C, Folli F, de Somer M, Traversa S, Inturrisi CE (2022) Esmethadone (REL-1017) and other uncompetitive NMDAR channel blockers may improve mood disorders via modulation of synaptic kinase-mediated signaling. Int J Mol Sci 23:12196. https:\/\/doi.org\/10.3390\/ijms232012196","journal-title":"Int J Mol Sci"},{"key":"1571_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.neuron.2019.03.013","volume":"102","author":"RS Duman","year":"2019","unstructured":"Duman RS, Sanacora G, Krystal JH (2019) Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron 102:75\u201390. https:\/\/doi.org\/10.1016\/j.neuron.2019.03.013","journal-title":"Neuron"},{"key":"1571_CR19","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","volume":"26","author":"J Bonaventura","year":"2021","unstructured":"Bonaventura J, Lam S, Carlton M, Boehm MA, Gomez JL, Solis O, Sanchez-Soto M, Morris PJ, Fredriksson I, Thomas CJ, Sibley DR, Shaham Y, Zarate CA Jr, Michaelides M (2021) Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol Psychiatry 26:6704\u20136722. https:\/\/doi.org\/10.1038\/s41380-021-01093-2","journal-title":"Mol Psychiatry"},{"key":"1571_CR20","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40263-022-00968-4","volume":"36","author":"SJ Keam","year":"2022","unstructured":"Keam SJ (2022) Dextromethorphan\/Bupropion: first approval. CNS Drugs 36:1229\u20131238. https:\/\/doi.org\/10.1007\/s40263-022-00968-4","journal-title":"CNS Drugs"},{"key":"1571_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","volume":"176","author":"V Popova","year":"2019","unstructured":"Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB (2019) Efficacy and safety of flexibly dosed Esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 176:428\u2013438. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19020172","journal-title":"Am J Psychiatry"},{"key":"1571_CR22","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1176\/appi.ajp.21080800","volume":"179","author":"H Tabuteau","year":"2022","unstructured":"Tabuteau H, Jones A, Anderson A, Jacobson M, Iosifescu DV (2022) Effect of AXS-05 (Dextromethorphan-Bupropion) in major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry 179:490\u2013499. https:\/\/doi.org\/10.1176\/appi.ajp.21080800","journal-title":"Am J Psychiatry"},{"key":"1571_CR23","doi-asserted-by":"publisher","first-page":"21m14345","DOI":"10.4088\/JCP.21m14345","volume":"83","author":"DV Iosifescu","year":"2022","unstructured":"Iosifescu DV, Jones A, O\u2019Gorman C, Streicher C, Feliz S, Fava M, Tabuteau H (2022) Efficacy and safety of AXS-05 (Dextromethorphan-Bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI). J Clin Psychiatry 83:21m14345. https:\/\/doi.org\/10.4088\/JCP.21m14345","journal-title":"J Clin Psychiatry"},{"key":"1571_CR24","doi-asserted-by":"publisher","first-page":"671859","DOI":"10.3389\/fphar.2021.671859","volume":"12","author":"S De Martin","year":"2021","unstructured":"De Martin S, Gabbia D, Folli F, Bifari F, Fiorina P, Ferri N, Stahl S, Inturrisi CE, Pappagallo M, Traversa S, Manfredi PL (2021) REL-1017 (Esmethadone) increases circulating BDNF levels in healthy subjects of a phase 1 clinical study. Front Pharmacol 12:671859. https:\/\/doi.org\/10.3389\/fphar.2021.671859","journal-title":"Front Pharmacol"},{"key":"1571_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1176\/appi.ajp.2021.21020197","volume":"179","author":"M Fava","year":"2022","unstructured":"Fava M, Stahl S, Pani L, De Martin S, Pappagallo M, Guidetti C, Alimonti A, Bettini E, Mangano RM, Wessel T, de Somer M, Caron J, Vitolo OV, DiGuglielmo GR, Gilbert A, Mehta H, Kearney M, Mattarei A, Gentilucci M, Folli F, Traversa S, Inturrisi CE, Manfredi PL (2022) REL-1017 (Esmethadone) as adjunctive treatment in patients with major depressive disorder: a phase 2a randomized double-blind trial. Am J Psychiatry 179:122\u2013131. https:\/\/doi.org\/10.1176\/appi.ajp.2021.21020197","journal-title":"Am J Psychiatry"},{"key":"1571_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1017\/S1092852922000359","volume":"27","author":"C Guidetti","year":"2022","unstructured":"Guidetti C, Fava M, Pani L, Pappagallo M, Serra G, DeMartin S, Mattarei A, Manfredi PL (2022) A phase 2a double-blind randomized trial of REL-1017 (Esmethadone) in patients with MDD: analysis of subscales from the symptoms of depression questionnaire. CNS Spectr 27:235. https:\/\/doi.org\/10.1017\/S1092852922000359","journal-title":"CNS Spectr"},{"key":"1571_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/s0304-3940(97)13391-2","volume":"223","author":"AL Gorman","year":"1997","unstructured":"Gorman AL, Elliott KJ, Inturrisi CE (1997) The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett 223:5\u20138. https:\/\/doi.org\/10.1016\/s0304-3940(97)13391-2","journal-title":"Neurosci Lett"},{"key":"1571_CR28","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3390\/ph15080997","volume":"15","author":"E Bettini","year":"2022","unstructured":"Bettini E, Stahl SM, De Martin S, Mattarei A, Sgrignani J, Carignani C, Nola S, Locatelli P, Pappagallo M, Inturrisi C, Bifari F, Cavalli A, Alimonti A, Pani L, Fava M, Traversa S, Folli F, Manfredi PL (2022) Pharmacological comparative characterization of REL-1017 (Esmethadone-HCl) and other NMDAR channel blockers in human heterodimeric N-methyl-D-aspartate receptors. Pharmaceuticals (Basel) 15:997. https:\/\/doi.org\/10.3390\/ph15080997","journal-title":"Pharmaceuticals (Basel)"},{"key":"1571_CR29","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1523\/JNEUROSCI.3703-08.2009","volume":"29","author":"SE Kotermanski","year":"2009","unstructured":"Kotermanski SE, Johnson JW (2009) Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer\u2019s drug memantine. J Neurosci 29:2774\u20132779. https:\/\/doi.org\/10.1523\/JNEUROSCI.3703-08.2009","journal-title":"J Neurosci"},{"key":"1571_CR30","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/JCP.0000000000001035","volume":"39","author":"G Bernstein","year":"2019","unstructured":"Bernstein G, Davis K, Mills C, Wang L, McDonnell M, Oldenhof J, Inturrisi C, Manfredi PL, Vitolo OV (2019) Characterization of the safety and pharmacokinetic profile of D-methadone, a novel N-methyl-D-aspartate receptor antagonist in healthy, opioid-naive subjects: results of two phase 1 studies. J Clin Psychopharmacol 39:226\u2013237. https:\/\/doi.org\/10.1097\/JCP.0000000000001035","journal-title":"J Clin Psychopharmacol"},{"key":"1571_CR31","doi-asserted-by":"publisher","first-page":"109219","DOI":"10.1016\/j.neuropharm.2022.109219","volume":"218","author":"JC Zhang","year":"2022","unstructured":"Zhang JC, Yao W, Hashimoto K (2022) Arketamine, a new rapid-acting antidepressant: a historical review and future directions. Neuropharmacology 218:109219. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109219","journal-title":"Neuropharmacology"},{"key":"1571_CR32","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/mp.2013.130","volume":"19","author":"G Sanacora","year":"2014","unstructured":"Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, Quirk MC (2014) Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry 19:978\u2013985. https:\/\/doi.org\/10.1038\/mp.2013.130","journal-title":"Mol Psychiatry"},{"key":"1571_CR33","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3390\/ph15070882","volume":"15","author":"E Bettini","year":"2022","unstructured":"Bettini E, De Martin S, Mattarei A, Pappagallo M, Stahl SM, Bifari F, Inturrisi CE, Folli F, Traversa S, Manfredi PL (2022) The N-methyl-D-aspartate receptor blocker REL-1017 (Esmethadone) reduces calcium influx induced by glutamate, quinolinic acid, and gentamicin. Pharmaceuticals (Basel) 15:882. https:\/\/doi.org\/10.3390\/ph15070882","journal-title":"Pharmaceuticals (Basel)"},{"key":"1571_CR34","unstructured":"Shram M, Henningfield J, Apseloff G, Gorodetzky C, De Martin S, Vocci F, Sapienza F, Kosten T, Huston J, Buchhalter A, Ashworth J, Lanier R, Folli F, Traversa S, Inturrisi CE, Manfredi P, Pappagallo M (2022) No meaningful abuse potential in recreational ketamine users of REL-1017 (Esmethadone Hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant. Paper presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. Scottsdale, AZ"},{"key":"1571_CR35","unstructured":"Shram M, Henningfield J, Apseloff G, Gorodetzky C, De Martin S, Vocci F, Sapienza F, Kosten T, Huston J, Buchhalter A, Ashworth J, Lanier R, Folli F, Traversa S, Inturrisi CE, Manfredi PL, Marco P (2022) No meaningful abuse potential in recreational opioid users of REL-1017 (Esmethadone Hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant. Paper presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. Scottsdale, AZ"},{"key":"1571_CR36","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0304-3940(89)90042-6","volume":"105","author":"DB Jaffe","year":"1989","unstructured":"Jaffe DB, Marks SS, Greenberg DA (1989) Antagonist drug selectivity for radioligand binding sites on voltage-gated and N-methyl-D-aspartate receptor-gated Ca2+ channels. Neurosci Lett 105:227\u2013232. https:\/\/doi.org\/10.1016\/0304-3940(89)90042-6","journal-title":"Neurosci Lett"},{"key":"1571_CR37","doi-asserted-by":"publisher","first-page":"863959","DOI":"10.3389\/fphar.2022.863959","volume":"13","author":"F Bifari","year":"2022","unstructured":"Bifari F, Pappagallo M, Bleavins M, Traversa S, Folli F, Manfredi PL (2022) REL-1017 (Esmethadone), a novel NMDAR blocker for the treatment of MDD is not neurotoxic in Sprague-Dawley rats. Front Pharmacol 13:863959. https:\/\/doi.org\/10.3389\/fphar.2022.863959","journal-title":"Front Pharmacol"},{"key":"1571_CR38","doi-asserted-by":"publisher","first-page":"106993","DOI":"10.1016\/j.ntt.2021.106993","volume":"87","author":"PJ Morris","year":"2021","unstructured":"Morris PJ, Burke RD, Sharma AK, Lynch DC, Lemke-Boutcher LE, Mathew S, Elayan I, Rao DB, Gould TD, Zarate CA Jr, Zanos P, Moaddel R, Thomas CJ (2021) A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801. Neurotoxicol Teratol 87:106993. https:\/\/doi.org\/10.1016\/j.ntt.2021.106993","journal-title":"Neurotoxicol Teratol"},{"key":"1571_CR39","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1126\/science.2660263","volume":"244","author":"JW Olney","year":"1989","unstructured":"Olney JW, Labruyere J, Price MT (1989) Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244:1360\u20131362. https:\/\/doi.org\/10.1126\/science.2660263","journal-title":"Science"},{"key":"1571_CR40","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1126\/science.1835799","volume":"254","author":"JW Olney","year":"1991","unstructured":"Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA (1991) NMDA antagonist neurotoxicity: mechanism and prevention. Science 254:1515\u20131518. https:\/\/doi.org\/10.1126\/science.1835799","journal-title":"Science"},{"key":"1571_CR41","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1006\/nbdi.1998.0206","volume":"5","author":"D Wozniak","year":"1998","unstructured":"Wozniak D, Dikranian K, Ishimaru M, Nardi A, Corso T, Tenkova T, Olney J, Fix A (1998) Disseminated corticolimbic neuronal degeneration induced in rat brain by MK-801: potential relevance to Alzheimer\u2019s disease. Neurobiol Dis 5:305\u2013322. https:\/\/doi.org\/10.1006\/nbdi.1998.0206","journal-title":"Neurobiol Dis"},{"key":"1571_CR42","first-page":"569","volume":"17","author":"NB Eddy","year":"1957","unstructured":"Eddy NB, Halbach H, Braenden OJ (1957) Synthetic substances with morphine-like effect: clinical experience; potency, side-effects, addiction liability. Bull World Health Organ 17:569\u2013863","journal-title":"Bull World Health Organ"},{"key":"1571_CR43","first-page":"1263","volume":"274","author":"EE Codd","year":"1995","unstructured":"Codd EE, Shank RP, Schupsky JJ, Raffa RB (1995) Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 274:1263\u20131270","journal-title":"J Pharmacol Exp Ther"},{"key":"1571_CR44","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1023\/A:1016355200944","volume":"3","author":"K Ramabadran","year":"1986","unstructured":"Ramabadran K, Bansinath M (1986) A critical analysis of the experimental evaluation of nociceptive reactions in animals. Pharm Res 3:263\u2013270. https:\/\/doi.org\/10.1023\/A:1016355200944","journal-title":"Pharm Res"},{"key":"1571_CR45","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1124\/jpet.102.035881","volume":"303","author":"EA Bolan","year":"2002","unstructured":"Bolan EA, Tallarida RJ, Pasternak GW (2002) Synergy between \u03bc opioid ligands: evidence for functional interactions among \u03bc opioid receptor subtypes. J Pharmacol Exp Ther 303:557\u2013562. https:\/\/doi.org\/10.1124\/jpet.102.035881","journal-title":"J Pharmacol Exp Ther"},{"key":"1571_CR46","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1213\/01.ane.0000205751.88422.41","volume":"102","author":"K Lemberg","year":"2006","unstructured":"Lemberg K, Kontinen VK, Viljakka K, Kyl\u00e4nlahti I, Yli-Kauhaluoma J, Kalso E (2006) Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat. Anesth Analg 102:1768\u20131774. https:\/\/doi.org\/10.1213\/01.ane.0000205751.88422.41","journal-title":"Anesth Analg"},{"key":"1571_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-15055-3","volume":"12","author":"J Henningfield","year":"2022","unstructured":"Henningfield J, Gauvin D, Bifari F, Fant R, Shram M, Buchhalter A, Ashworth J, Lanier R, Pappagallo M, Inturrisi C (2022) REL-1017 (Esmethadone; d-Methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats. Sci Rep 12:1\u201315. https:\/\/doi.org\/10.1038\/s41598-022-15055-3","journal-title":"Sci Rep"},{"key":"1571_CR48","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1001\/archinte.1948.00020040042004","volume":"82","author":"H Isbell","year":"1948","unstructured":"Isbell H, Wilker A, Eisenman AJ, Daingerfield M, Frank K (1948) Liability of addiction to 6-dimethylamino-4-4-diphenyl-3-heptanone (Methadon, Amidone or 10820) in man: experimental addiction to methadon. Arch Intern Med 82:362\u2013392. https:\/\/doi.org\/10.1001\/archinte.1948.00020040042004","journal-title":"Arch Intern Med"},{"key":"1571_CR49","first-page":"25","volume":"14","author":"H Fraser","year":"1962","unstructured":"Fraser H, Isbell H (1962) Human pharmacology and addictiveness of certain dextroisomers of synthetic analgesics. Bull Narc 14:25\u201335","journal-title":"Bull Narc"},{"key":"1571_CR50","unstructured":"Drug Enforcement Administration (2019) Methadone. Drug Enforcement Administration. https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/methadone\/methadone.pdf. Accessed 11 Nov 2022"},{"key":"1571_CR51","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1124\/pr.112.007138","volume":"65","author":"GW Pasternak","year":"2013","unstructured":"Pasternak GW, Pan Y-X (2013) Mu opioids and their receptors: evolution of a concept. Pharmacol Rev 65:1257\u20131317. https:\/\/doi.org\/10.1124\/pr.112.007138","journal-title":"Pharmacol Rev"},{"key":"1571_CR52","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40263-021-00891-0","volume":"36","author":"M Pappagallo","year":"2022","unstructured":"Pappagallo M, Inturrisi CE, Manfredi PL (2022) Comment on \u201cNovel glutamatergic modulators for the treatment of mood disorders: current status.\u201d CNS Drugs 36:203\u2013204. https:\/\/doi.org\/10.1007\/s40263-021-00891-0","journal-title":"CNS Drugs"},{"key":"1571_CR53","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/15622970802416057","volume":"10","author":"M Soyka","year":"2009","unstructured":"Soyka M, Zingg C (2009) Feasability and safety of transfer from racemic methadone to (R)-methadone in primary care: clinical results from an open study. World J Biol Psychiatry 10:217\u2013224. https:\/\/doi.org\/10.1080\/15622970802416057","journal-title":"World J Biol Psychiatry"},{"key":"1571_CR54","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1037\/pha0000310","volume":"28","author":"T Hanania","year":"2020","unstructured":"Hanania T, Manfredi P, Inturrisi C, Vitolo OV (2020) The N-methyl-D-aspartate receptor antagonist d-methadone acutely improves depressive-like behavior in the forced swim test performance of rats. Exp Clin Psychopharmacol 28:196\u2013201. https:\/\/doi.org\/10.1037\/pha0000310","journal-title":"Exp Clin Psychopharmacol"},{"key":"1571_CR55","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fncel.2019.00087","volume":"13","author":"MV Foga\u00e7a","year":"2019","unstructured":"Foga\u00e7a MV, Duman RS (2019) Cortical GABAergic dysfunction in stress and depression: new insights for therapeutic interventions. Front Cell Neurosci 13:87. https:\/\/doi.org\/10.3389\/fncel.2019.00087","journal-title":"Front Cell Neurosci"},{"key":"1571_CR56","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40263-018-0519-3","volume":"32","author":"P Molero","year":"2018","unstructured":"Molero P, Ramos-Quiroga JA, Martin-Santos R, Calvo-S\u00e1nchez E, Guti\u00e9rrez-Rojas L, Meana JJ (2018) Antidepressant efficacy and tolerability of Ketamine and Esketamine: a critical review. CNS Drugs 32:411\u2013420. https:\/\/doi.org\/10.1007\/s40263-018-0519-3","journal-title":"CNS Drugs"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-023-01571-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-023-01571-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-023-01571-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T05:05:31Z","timestamp":1693285531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-023-01571-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1571"],"URL":"https:\/\/doi.org\/10.1007\/s00406-023-01571-4","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"assertion":[{"value":"28 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Relmada Therapeutics and its consultants and employees contributed to all aspects of this manuscript, including all described experimental work.\u00a0","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}